Starting from a previously validated molecule is one of the fastest ways to reach the clinic, but the IP economics are unforgiving. Molecules that closely track prior art offer weak IP protection, and method-of-use claims often fail to defend a market position. Integrated drug discovery (IDD) services solve this by co-locating chemistry and biology teams and embedding IP-aware design into the chemistry from the outset, helping companies turn validated starting points into novel, patentable chemical entities.
